2-amino-6-phenyl-4,5,6,7-tetrahydrobenzo[b]thiophene-3-carboxamide | 937648-16-3

• 分子结构分类: 有机化合物 - 有机杂环化合物
• 英文名称: 2-amino-6-phenyl-4,5,6,7-tetrahydrobenzo[b]thiophene-3-carboxamide
• 英文别名: 2-Amino-6-phenyl-4,5,6,7-tetrahydro-1-benzothiophene-3-carboxamide
• CAS: 937648-16-3
• 化学式: C₁₅H₁₆N₂OS
• 分子量: 272.371
• InChiKey: YTKDAJZBVQKUNZ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.3
• 重原子数：
  19
• 可旋转键数：
  2
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.27
• 拓扑面积：
  97.4
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  2-amino-6-phenyl-4,5,6,7-tetrahydrobenzo[b]thiophene-3-carboxamide 在 四氯苯醌 作用下， 以 1,4-二氧六环 为溶剂， 反应 5.0h， 生成
  参考文献：
  名称：

  Aryl extensions of thienopyrimidinones as fibroblast growth factor receptor 1 kinase inhibitors

  摘要：

  Optimization of thienopyrimidinone derivatives as FGFR1 kinase inhibitors is being pursued. The present results confirm predictions of computational modeling that an aryl substituent can be introduced at the 2-position in structure 3. The substituent is anticipated to project deeper into the binding site and provide opportunities for enhanced activity and selectivity. The most potent analog reported herein, 13, has a 4-hydroxyphenyl substituent and yields an IC(50) of 6 mu M for inhibition of phosphorylation by FGFR1 kinase. It was also found that the western anisole-containing substituent in 3 can be replaced by a propionic acid group with no loss in potency and with potentially significant gains in pharmacologically relevant properties. (C) 2010 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.tetlet.2010.12.081
• 作为产物：
  描述：

  4-phenyl-3-cyclohexen-1-one 在 哌啶 、 palladium 10% on activated carbon 、 氢气 、 sulfur 作用下， 以 乙醇 、 乙酸乙酯 为溶剂， 反应 20.0h， 生成 2-amino-6-phenyl-4,5,6,7-tetrahydrobenzo[b]thiophene-3-carboxamide
  参考文献：
  名称：

  Aryl extensions of thienopyrimidinones as fibroblast growth factor receptor 1 kinase inhibitors

  摘要：

  Optimization of thienopyrimidinone derivatives as FGFR1 kinase inhibitors is being pursued. The present results confirm predictions of computational modeling that an aryl substituent can be introduced at the 2-position in structure 3. The substituent is anticipated to project deeper into the binding site and provide opportunities for enhanced activity and selectivity. The most potent analog reported herein, 13, has a 4-hydroxyphenyl substituent and yields an IC(50) of 6 mu M for inhibition of phosphorylation by FGFR1 kinase. It was also found that the western anisole-containing substituent in 3 can be replaced by a propionic acid group with no loss in potency and with potentially significant gains in pharmacologically relevant properties. (C) 2010 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.tetlet.2010.12.081

文献信息

• Syntheses and biological evaluation of 2-amino-3-acyl-tetrahydrobenzothiophene derivatives; antibacterial agents with antivirulence activity
  作者：Hung The Dang、Erik Chorell、Hanna Uvell、Jerome S. Pinkner、Scott J. Hultgren、Fredrik Almqvist

  DOI：10.1039/c3ob42478b

  日期：——

  by pilicides) is a promising approach to combating bacterial infection. A high-throughput screening campaign of a library of 17 500 small molecules identified 2-amino-3-acyl-tetrahydrobenzothiophene derivatives (hits 2 and 3) as novel inhibitors of pili-dependent biofilm formation in a uropathogenic Escherichia coli strain UTI89. Based on compounds 2 and 3 as the starting point, we designed and synthesized

  开发针对毒力因子的新化合物（例如，通过pilicides 抑制菌毛组装）是对抗细菌感染的一种有前途的方法。一个由 17500 个小分子组成的文库的高通量筛选活动将 2-氨基-3-酰基-四氢苯并噻吩衍生物（命中2和3）鉴定为泌尿致病性大肠杆菌菌株 UTI89中菌毛依赖性生物膜形成的新型抑制剂。以化合物2和3为出发点，我们设计合成了一系列结构相关的类似物，并研究了它们对大肠杆菌生物膜形成的活性UTI89。初始命中的系统结构修改为其 SAR 提供了有价值的信息，以供进一步优化。此外，母体分子的小结构变化导致大肠杆菌生物膜发育的低微摩尔抑制剂 ( 20-23 )，而对细菌生长没有影响。在血凝 (HA) 滴度测定和电子显微镜 (EM) 测量中证实命中化合物3及其类似物20可防止菌毛形成。这些发现表明，2-氨基-3-酰基-四氢苯并噻吩可以作为一类新的化合物，进一步作为具有抗毒力活性的抗菌剂。
• Activation of Elemental Sulfur by Electrogenerated Cyanomethyl Anion: Synthesis of Substituted 2-Aminothiophenes by the Gewald Reaction
  作者：Marta Feroci、Isabella Chiarotto、Leucio Rossi、Achille Inesi

  DOI：10.1002/adsc.200800503

  日期：——

  The activation of elemental sulfur (S8) has been achieved by means of electrogenerated cyanomethyl anion [easily obtained by galvanostatic reduction from acetonitrile/tetraethylammonium hexafluorophosphate (MeCN-Et4NPF6)]. The “activated” sulfur reacted with ylidenemalononitriles to give substituted 2-aminothiophenes in very high yields. This variation of the Gewald reaction has been carried out using

  元素硫（S 8）的活化已通过电生成的氰基甲基阴离子实现[从乙腈/六氟磷酸四乙铵（MeCN-Et 4 NPF 6）通过恒电流还原可轻松获得]。“活化的”硫与亚甲基丙二腈反应，以非常高的产率得到取代的2-氨基噻吩。盖瓦尔德反应的这种变化仅使用催化量的电和支持电解质来进行。描述了S 8和氰基甲基阴离子之间相互作用的拟议机理。
• [EN] POSITIVE ALLOSTERIC MODULATORS OF DOPAMINE 1 RECEPTOR AND METHOD OF USE THEREOF<br/>[FR] MODULATEURS ALLOSTÉRIQUES POSITIFS DU RÉCEPTEUR DE LA DOPAMINE 1 ET PROCÉDÉ D'UTILISATION ASSOCIÉ
  申请人：US HEALTH

  公开号：WO2019173437A1

  公开（公告）日：2019-09-12

  Disclosed are compounds of formulas (I) and (III) for treating or preventing a disease or disorder responsive to activation of a D1 dopamine receptor agonist in a mammal in need thereof, wherein R1 R6 and R11 R13 are as defined herein. Examples of such disease or disorder include Alzheimer's Disease, schizophrenia, Parkinson's disease, a dyskinesia, and Huntington's disease.

  本发明揭示了式(I)和式(III)的化合物，用于治疗或预防哺乳动物中D1多巴胺受体激动剂的激活所响应的疾病或障碍，其中R1、R6和R11、R13如本文所定义。此类疾病或障碍的例子包括阿尔茨海默病、精神分裂症、帕金森病、运动障碍和亨廷顿病。
• Identification of PDE4B Over 4D subtype-selective inhibitors revealing an unprecedented binding mode
  作者：Michael Kranz、Michael Wall、Brian Evans、Afjal Miah、Stuart Ballantine、Chris Delves、Brian Dombroski、Jeffrey Gross、Jessica Schneck、James P. Villa、Margarete Neu、Don O. Somers

  DOI：10.1016/j.bmc.2009.03.061

  日期：2009.7

  A PDE4B over 4D-selective inhibitor programme was initiated to capitalise on the recently discovered predominance of the PDE4B subtype in inflammatory cell regulation. The SAR of a tetrahydrobenzothiophene (THBT) series did not agree with either of two proposed docking modes in the 4B binding site. A subsequent X-ray co- crystal structure determination revealed that the THBT ligand displaces the Gln-443 residue, invariably ligand-anchoring in previous PDE4 co-crystal structures, and even shifts helix-15 by 1-2 angstrom. For the first time, several residues of the C-terminus previously proposed to be involved in subtype selectivity are resolved and three of them extend into the ligand binding site potentially allowing for selective drug design. (C) 2009 Elsevier Ltd. All rights reserved.
• POSITIVE ALLOSTERIC MODULATORS OF DOPAMINE 1 RECEPTOR AND METHOD OF USE THEREOF
  申请人：The United States of America, as represented by the Secretary, Department of Health and Human Services

  公开号：EP3762383A1

  公开（公告）日：2021-01-13